Nuclear structural proteins as biomarkers of cancer
โ Scribed by Badrinath R. Konety; Robert H. Getzenberg
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 67 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
โฆ Synopsis
The regulation of cell processes is integrally connected to cellular and extracellular structure. Studies over the past three decades have demonstrated the complex interactions of cell structure and function. The relationship of cellular structure and function has perhaps been most studied in the transformed cell. The hallmark of transformation is alterations in the shape of the cell and the nucleus. Many of the cellular alterations observed in the cancer process are structural, including changes in extracellular matrix-cytoskeletal interactions, cytoskeletal elements, as well as nuclear structure. This review focuses on the structural components of the nucleus, the nuclear matrix, and their role in the cancer process and the use of these structural components of the nucleus, the nuclear matrix, and their role in the cancer process and the use of these structural components as cancer specific biomarkers.
๐ SIMILAR VOLUMES
## Background: Immunohistochemical methods were used to study the pattern of expression of tenascin (tn) in invasive colon cancer and its relation to prognosis. ## Methods: Sixty patients (29 males, 31 females) with a mean age of 77 years were studied. tn expression was evaluated by immunohistoch
The use of nuclear morphometry as an intermediate endpoint biomarker is described in a Phase I, dose-seeking trial of chemoprevention of cervical cancer, using the agent โฃ-difluoromethylornithine (DFMO). Thirty patients with grade III cervical intraepithelial neoplasia (CIN III) were enrolled, and t
Nuclear morphometric features including nuclear area (NA), nuclear perimeter (PE), their variation (SDNA, SDPE), and mean largest and smallest nuclear diameters (Dmax, Dmin) were examined in 116 patients with stage I-II gastric adenocarcinoma. Morphometric measurements were compared with tumour diff
To assess the value of estrogen receptor protein (ERP) as a predictor of tumor recurrence, 556 patients treated by mastectomy between 1973 and 1978 for primary operable breast cancer had ERP determination of their tumors. All patients had histologically negative nodes. Two hundred fifty-six patients